Oral direct-acting antiviral therapy to prevent reinfection of the liver graft after liver transplantation for hepatitis C virus-related cirrhosis

摘要

Hepatitis C virus (HCV) remains the most common indication for orthotopic liver transplantation (OLT) and universally reinfects the new liver graft; as a result, patients with HCV have poorer outcomes than patients undergoing OLT for non-HCV-related cirrhosis. Recently, new direct-acting antiviral (DAA) agents have been approved for genotype 1 HCV infections in combination with peginterferon/ribavirin (RBV). However, these therapies may be associated with morbidity and mortality when they are given to patients with advanced liver disease.4 We report a sustained response with an oral DAA/RBV combination without interferon in a 61-yearold male with HCV genotype 1b (interleukin-28B TT) who underwent OLT at our center for HCV-related cirrhosis.